phase I study of radiosensitization using bortezomib in patients with relapsed mantle cell or aggressive lymphoma receiving radioimmunotherapy.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2010
At a glance
- Drugs Bortezomib; Tositumomab
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 25 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Mar 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 12 Feb 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov, last updated 12 Feb 2009.